Truvestments Capital’s Dyne Therapeutics DYN Stock Holding History

Truvestments Capital’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.35K	Hold	295	–	–	﹤0.01%	871
2025 Q4	$5.77K	Hold	295	–	–	﹤0.01%	785
2025 Q3	$3.73K	Hold	295	–	–	﹤0.01%	869
2025 Q2	$2.81K	Hold	295	–	–	﹤0.01%	800
2025 Q1	$3.09K	Hold	295	–	–	﹤0.01%	812
2024 Q4	$6.95K	Hold	295	–	–	﹤0.01%	659
2024 Q3	$10.6K	Buy	+295	New	+$11.7K	﹤0.01%	574
2024 Q2	–	Sell	-464	Closed	-$13.2K	–	367
2024 Q1	$13.2K	Hold	464	–	–	0.01%	477
2023 Q4	$6.17K	Hold	464	–	–	﹤0.01%	571
2023 Q3	$4.16K	Hold	464	–	–	﹤0.01%	526
2023 Q2	$5.22K	Hold	464	–	–	﹤0.01%	523
2023 Q1	$5.34K	Buy	+464	New	+$6.03K	﹤0.01%	503

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Truvestments Capital's DYN Position: Q1 2026 in Review

Truvestments Capital held its Dyne Therapeutics (DYN) position steady in Q1 2026 at 295 shares worth $5.35K. The position accounts for ﹤0.01% of the portfolio, ranked #871.

Truvestments Capital first reported a position in DYN in Q1 2023 and has held it in 12 quarters since. The position peaked at $13.2K in Q1 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Truvestments Capital held 295 shares of Dyne Therapeutics worth $5.35K as of Q1 2026.
Truvestments Capital left its Dyne Therapeutics share count unchanged in Q1 2026.
Dyne Therapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q1 2026, its #871 holding.
Truvestments Capital first reported a position in Dyne Therapeutics in Q1 2023 and has held it in 12 quarters since.
Truvestments Capital's Dyne Therapeutics position peaked at $13.2K in Q1 2024.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.